What s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis
|
|
- Marybeth Grant
- 5 years ago
- Views:
Transcription
1 What s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis A combination of improved surgical techniques, donor organ preservation, selection criteria and immunosuppressive drugs have all markedly decreased short term complications in the liver allograft, leading to longer graft and patient survival. Current diagnostic and therapeutic challenges therefore revolve around long-term complications in the allograft which include rejection, recurrent disease, tumor occurrence and poorly characterized lesions such as architectural alterations and fibrosis. This talk will focus on recently characterized patterns of rejection occurring in the late post-transplantation period. Rejection in the liver allograft Rejection in the liver allograft has been historically classified into acute and chronic rejection. The former is characterized by infiltration of the allograft by immune cells which represent a reaction of the host immune system against donor antigens located on the graft. This cellular process can be abrogated by administration of immunosuppressive drugs which suppress the host response. Chronic rejection, which is characterized by obliterative arteriopathy and damage to bile ducts, does not show a similar infiltration of the allograft by donor host cells; administration of immunosuppressive drugs, therefore does not have a major role, if any, in chronic rejection. Acute rejection Inspite of the moniker acute, this type of rejection may occur anytime, including many years, after transplantation. It is thus better labeled as cellular rejection with the terms acute/early or late being used to define the timing of cellular rejection after transplantation. The histological appearance of cellular rejection occurring within the first 3 6 months of transplantation (acute/ early cellular rejection) is well recognized and consists of the classic triad of mixed portal inflammatory infiltrate, bile duct damage, and endothelitis. In contrast, the histological features of cellular rejection occurring 3 6 months after transplantation (late cellular rejection) do not show this classical triad. At this stage, the inflammatory infiltrate is not mixed and consists predominantly of mature appearing lymphocytes without as many neutrophils and eosinophils. Endothelitis is not present and bile duct damage is mild. The features may thus resemble chronic hepatitis. Distinct patterns of late cellular rejection Three additional patterns of injury are now increasingly believed to represent late rejection; these are central perivenulitis, plasma cell hepatitis and chronic hepatitis. Although these are mainly cellular patterns of rejection, there is some evidence that antibody mediated mechanisms may also be at play, at least partially. Unhappily, all three patterns of injury may be caused by a variety of non-rejection etiologies, including recurrent hepatitis C. The challenge lies in establishing a diagnostic distinction between late rejection and other competing causes, especially recurrent hepatitis C. Central perivenulitis Central perivenulitis (CP) is a necroinflammatory process localized to the central veins and the perivenular zone of hepatocytes. The lesion is characterized by variable degrees of inflammatory infiltrate, endothelitis, hepatocyte loss, extravasation of red blood cells and perivenular fibrosis. The inflammatory infiltrate consists of variable combinations of plasma cells, lymphocytes, and eosinophils. Central perivenulitis may occur with or without concomitant portal tract changes. When accompanying portal changes are present, they may provide clues to the underlying process causing central perivenulitis. When CP occurs without portal tract changes, the lesion is referred to as isolated central perivenulitis 1
2 (ICP) and the underlying etiology is more difficult to tease out. CP with portal tract changes may occur both early and late after transplantation whereas ICP occurs most often 6 months to 1 year after transplantation. Cases presenting initially as ICP may show portal changes in subsequent biopsies. ICP has been reported in approximately one-third of both adult and pediatric transplant recipients. A subset of patients who present with ICP on their biopsies have been transplanted for autoimmune hepatitis or primary biliary cirrhosis and progress to typical portal changes of recurrent disease in subsequent biopsies. In the remaining cases, the differential diagnosis includes late cellular rejection, recurrent hepatitis C infection, and drug-induced hepatitis. The distinction of recurrent hepatitis C from late cellular rejection cannot be overemphasized. The diagnosis of rejection can be reliably made only when the majority, or at least 50%, of central veins are involved; a localized reaction involving only a minority of central veins is not indicative of rejection. In addition, patients with ICP due to rejection have had prior episodes of acute rejection, many with central perivenulitis. Serum levels of viral nucleic acids and recent history of immunosuppression aid in the differential diagnosis. Evidence that central perivenulitis represents late cellular rejection includes decreased incidence of perivenular fibrosis in patients treated with immunosuppression, progression of untreated patients to chronic ductopenic rejection and increased incidence of prior episodes of rejection in patients with ICP. Clinically patients may be asymptomatic or there may be mild elevations of liver tests; in contrast to portal-based rejection, transaminases are elevated more than the biliary enzymes. Some patients may miss clinical detection altogether and present with ascites and clinical suspicion of Budd-Chiari syndrome or veno-occlusive disease. While minimal or mild cases of CP resolve spontaneously, an increased incidence of perivenular fibrosis has been observed in patients with moderate to severe CP who are not treated with immunosuppression. CP is more resistant to therapy than portal based rejection and it is believed that this lesion indicates transition from acute to chronic rejection. Acetaminophen toxicity, venous outflow block and ischemic hepatitis all affect the perivenular zone of the liver. However, none of these conditions is characterized by an inflammatory response similar to that seen in CP. Acetaminophen toxicity and ischemic hepatitis demonstrate coagulative necrosis of zone 3 hepatocytes in the absence of significant inflammation. Venous outflow block shows sinusoidal dilatation and congestion with or without hepatic plate compression in the absence of significant inflammation. Not uncommonly, central perivenulitis, whether isolated or occurring with portal tract changes, may consist of a predominantly plasma cell infiltrate. This lesion is discussed next. 2
3 Diagnostic approach to central perivenulitis (Saxena R. Practical Hepatic Pathology, 2011) Plasma cell hepatitis A distinctive inflammatory process resembling autoimmune hepatitis (AIH) in the native liver occurs in liver allografts in the late posttransplant period. The inflammatory infiltrate consists predominantly of plasma cells, and it may involve the central veins (central perivenulitis), the portal tracts or both. Not infrequently, central perivenulitis may precede the appearance of a plasma cell-rich portal inflammatory infiltrate. 3
4 When involved, the portal tracts are expanded by an inflammatory infiltrate consisting predominantly of plasma cells; variable degrees of interface activity and portal fibrosis are seen. When involving the central veins, there is a rich plasma cell infiltrate around the central veins, accompanied by cell loss and extravasation of red blood cells. When occurring in patients transplanted for AIH, this pattern of injury is generally considered to represent recurrent disease. When occurring in patients not transplanted for AIH, the lesion has been referred to as de novo AIH, plasma cell hepatitis, and plasma cell-rich AIH-like hepatitis. The term plasma cell hepatitis is preferred by this author for its brevity and for being accurately descriptive without any etiologic implications. Plasma cell hepatitis has been reported most often in pediatric patients, patients transplanted for autoimmune diseases such as primary biliary cirrhosis and primary sclerosing cholangitis, and patients transplanted for chronic hepatitis C. Whereas some patients may demonstrate increased levels of serum immunoglobulins and autoimmune antibodies, this is certainly not the norm. Treatment with steroids leads to biochemical and histological improvement in most cases. However, this therapeutic option is potentially risky in patients transplanted for hepatitis C; the finding of plasma cell hepatitis in this group of patients therefore presents considerable diagnostic and therapeutic challenges. The interplay between the hepatitis C virus and the host immune response, already complex and not well understood, becomes even more so complex in the setting of transplantation and the effects of modulation of the host immune response by interferon therapy on one hand and immunosuppressive regimens on the allograft cannot always be predicted. Thus, plasma cell hepatitis occurring in patients transplanted for hepatitis C has been variously thought to represent an atypical morphological variant of recurrent hepatitis C infection, rejection following rearming of the body s immunological system following interferon treatment with and a drug (interferon)-induced auto immune hepatitis. In nontransplanted individuals, chronic hepatitis C infection has been associated with autoimmune phenomenon such as increased serum immunoglobulins, autoantibodies, mixed cryoglobulinemia, and extrahepatic autoimmune diseases. Autoimmune features may also be triggered by interferon treatment. The liver disease in these patients pursues a more aggressive course and the prognosis is worse. In transplanted individuals, plasma cell hepatitis may occur following interferon therapy for treatment of hepatitis C. These patients may also develop extrahepatic autoimmune disorders and respond favorably to prednisone. Interferon therapy has been associated with an increased risk of progressing to chronic rejection. These data suggest that plasma cell hepatitis represents an alloimmune response triggered by interferon, probably due to re-arming of the host immune response; the distinction between rejection and auto immune hepatitis being somewhat moot. A case controlled study of patients transplanted for hepatitis C infection found that plasma cell hepatitis was associated suboptimal immunosuppression and resolved when immunosuppression was increased, strengthening the view that interferon treatment triggers rejection, especially if the patient is not adequately immunosuppressed. 4
5 Diagnostic approach to plasma cell hepatitis (Saxena R. Practical Hepatic Pathology) Idiopathic posttransplant chronic hepatitis Chronic hepatitis in the liver allograft may be caused by recurrent autoimmune or viral hepatitis, de novo viral hepatitis or drug-induced hepatitis. Some cases of chronic hepatitis may evolve into recurrent primary biliary cirrhosis on subsequent biopsies. However, a significant subset of patients do not have a well-defined cause and constitute the group of cases with idiopathic posttransplant chronic hepatitis (IPTH). The incidence of IPTH varies widely between centers and is more prevalent in those that routinely perform protocol biopsies in long-term allografts, revealing that IPTH is most often a subclinical condition. Overall, IPTH has been reported in one-third to one-half of all liver biopsies taken 12 months after transplantation. The incidence is higher in children than in adults. No correlation has been found between the incidence of IPTH and the original indication for transplantation Histologically, there is a mononuclear inflammatory infiltrate in portal tracts with variable degrees of spillover/interface hepatitis and fibrosis. There is no endothelitis. Mild bile duct damage may be present in some cases but bile ducts are not lost. Varying degrees of lobular inflammation may be seen but is usually mild. There may be mild central perivenulitis. The severity of IPTH may increase or decrease over time or remain unchanged. 5
6 Evidence that IPTH represents a form of late cellular rejection comes from the increased incidence of graft failure due to cirrhosis in patients with IPTH. The incidence of cirrhosis is less in those centers that treat IPTH with immunosuppression. IPTH appears to be more common in patients who have had previous episodes of acute cellular rejection, including CP. The diagnosis of IPTH necessitates the exclusion of all known causes of hepatitis which includes recurrent viral and autoimmune hepatitis and de novo viral hepatitis. Diagnostic approach to posttransplant chronic hepatitis (Saxena R. Practical Hepatic Pathology, 2011) 6
7 References 1. Abraham SC, Freese DK, Ishitani MB, et al: Significance of central perivenulitis in pediatric liver transplantation. Am J Surg Pathol 2008;32: Krasinskas AM, Demetris AJ, Poterucha JJ, et al: The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl 2008;14: Krasinskas AM, Ruchelli ED, Rand EB, et al: Central venulitis in pediatric liver allografts. Hepatology 2001;33: Sebagh M, Debette M, Samuel D, et al: Silent presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 1999;30: Sebagh M, Rifai K, Feray C, et al: All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003;37: Tsamandas AC, Jain AB, Felekouras ES, et al: Central venulitis in the allograft liver: A clinicopathologic study. Transplantation 1997;64: Hubscher SG: Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl 2008;14: Evans HM, Kelly DA, McKiernan PJ, et al: Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43: Miyagawa-Hayashino A, Haga H, Egawa H, et al: Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004;78: Syn WK, Nightingale P, Gunson B, et al: Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007;13: Shaikh OS, Demetris AJ: Idiopathic posttransplantation hepatitis? Liver Transpl 2007;13: Ekong UD, Melin-Aldana H, Seshadri R, et al: Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl 2008;14: Mells G, Mann C, Hubscher S, et al: Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl 2009;15: Mells G, Neuberger J: Protocol liver allograft biopsies. Transplantation 2008;85: Fiel MI, Agarwal K, Stanca C, et al: Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008;14: Khettry U, Huang WY, Simpson MA, et al: Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007;38: Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al: Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108: Berardi S, Lodato F, Gramenzi A, et al: High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56: Stanca CM, Fiel MI, Kontorinis N, et al: Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007;84: Yoshitomi M, Koshiba T, Haga H, et al: Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009;87: Berenguer M, Aguilera V, Prieto M, et al: Significant improvement in the outcome of HCVinfected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44: Berenguer M, Rayon JM, Prieto M, et al: Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001;7: Nakhleh RE, Krishna M, Keaveny AP, et al: Review of 31 cases of morphologic hepatitis in liver transplant patients not related to disease recurrence. Transplant Proc 2005;37:
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationLiver neoplasm - Biology and classification
Liver neoplasm - Biology and classification Young Nyun Park, M.D., Ph.D. Department of Pathology, Yonsei University College of Medicine, Seoul, Korea In this lecture, precursor lesions and recently introduced
More information11 th Banff Conference on Allograft Pathology - An Update
11 th Banff Conference on Allograft Pathology - An Update Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth Hospital, Birmingham Enghien les
More informationHistopathological Causes of Late Liver Allograft Dysfunction: Analysis at a Single Institution
The Korean Journal of Pathology 2013; 47: 21-27 ORIGINAL ARTICLE Histopathological Causes of Late Liver Allograft Dysfunction: Analysis at a Single Institution Eun Shin Ji Hoon Kim 1 Eunsil Yu 1 Department
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationLiver Transplant Pathology a general view
Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?
More informationHistopathology of De Novo Autoimmune Hepatitis
LIVER TRANSPLANTATION 18:811-818, 2012 ORIGINAL ARTICLE Histopathology of De Novo Autoimmune Hepatitis Ananya Pongpaibul, 1 Robert S. Venick, 2 Sue V. McDiarmid, 3 and Charles R. Lassman 4 1 Department
More informationAutoimmune hepatitis
Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune
More informationLate Protocol Liver Biopsies in the Liver Allograft: A Neglected Investigation?
LIVER TRANSPLANTATION 15:931-938, 2009 ORIGINAL ARTICLE Late Protocol Liver Biopsies in the Liver Allograft: A Neglected Investigation? George Mells, 1 Caroline Mann, 1 Stefan Hubscher, 2 and James Neuberger
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationAllograft Hepatitis after Liver Transplantation for Epithelioid Haemangioendothelioma
214) Prague Medical Report / Vol. 110 (2009) No. 3, p. 214 221 Allograft Hepatitis after Liver Transplantation for Epithelioid Haemangioendothelioma Honsová E. 1, Gottfriedová H. 2, Oliverius M. 3, Trunečka
More informationAMR in Liver Transplantation: Incidence
AMR in Liver Transplantation: Incidence Primary AMR 1/3 to 1/2 of ABO-incompatible transplants Uncommon with ABO-compatible transplant Secondary AMR Unknown incidence: rarely tested Why is AMR uncommon
More informationChronic liver allograft dysfunction. An unsolved problem
Chronic liver allograft dysfunction An unsolved problem % patient survival % patient survival 100 Kaplan-Meier estimates by sex and age group 100 90 90 80 80 70 70 60 60 50 50 40 40 30 20 10 Males Females
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt
More informationPITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017
CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 I HAVE NOTHING TO DISCLOSE Linda Ferrell PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES Linda Ferrell, MD, UCSF THE PROBLEM
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationBanff Schema for Grading Liver Allograft Rejection: Utility in Clinical Practice
Banff Schema for Grading Liver Allograft Rejection: Utility in Clinical Practice Donald G. Ormonde,* W. Bastiaan de Boer, Anthony Kierath, Roger Bell, Keith B. Shilkin, Anthony K. House, Gary P. Jeffrey,*,
More informationInterpretation of Biopsy Findings in the Transplant Liver
Interpretation of Biopsy Findings in the Transplant Liver Kirk D. Jones, MD and Linda D. Ferrell, MD W i several thousand liver transplants being performed each year and many patients being managed in
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationAutoimmune Liver Diseases
2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012
More informationFigure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.
New Insights into Antibody Mediated Graft Injury after Pediatric Liver Transplantation S.V. McDiarmid MD Professor of Pediatrics and Surgery David Geffen School of Medicine University of California, Los
More informationRecurrence of autoimmune liver diseases after liver transplantation: clinical aspects
Autoimmun Highlights (2012) 3:113 118 DOI 10.1007/s13317-012-0040-5 REVIEW ARTICLE Recurrence of autoimmune liver diseases after liver transplantation: clinical aspects Evangelos Cholongitas Andrew K.
More informationCentrilobular necrosis (CN) has been reported in
RAPID COMMUNICATION Centrilobular Necrosis After Orthotopic Liver Transplantation: Association With Acute Cellular Rejection and Impact on Outcome Ziad Hassoun, 1 Vijay Shah, 1 Christine M. Lohse, 2 V.
More informationChronic rejection (CR) is one of the causes of late liver
Accuracy of Bile Duct Changes for the Diagsis of Chronic Liver Allograft Rejection: Reliability of the 1999 Banff Schema Mylène Sebagh, 1 Karin Blakolmer, 1 Bru Falissard, 3 Bru Roche, 2 Jean-Francois
More informationHepatitis C recurrence is virtually universal after liver
GASTROENTEROLOGY 2012;142:1132 1139 Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon JOSH LEVITSKY,* MARIA ISABEL
More informationCase Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation
108 Diagnostic Problems in Hepatology Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation Brian Kim, MD 1 Anshu Trivedi, MD
More informationSlide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.
Many of the histologic images and the tables are from MacSween s Pathology of the Liver (5 th Edition). Other images were used from an online source called PathPedia.com. A few images from other sources
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationEffect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients
LIVER TRANSPLANTATION 12:762-767, 2006 ORIGINAL ARTICLE Effect of Calcineurin Inhibitors on Survival and Histologic Disease Severity in HCV-Infected Liver Transplant Recipients Marina Berenguer, 1 Victoria
More informationNon-Cirrhotic Portal Hypertension and Incomplete Septal Cirrhosis. Stefan Hübscher, University of Birmingham, Birmingham B15 2TT, U.K.
Non-Cirrhotic Portal Hypertension and Incomplete Septal Cirrhosis Stefan Hübscher, University of Birmingham, Birmingham B15 2TT, U.K. Non-Cirrhotic Portal Hypertension Problems with Liver Biopsy Diagnosis
More informationLiver transplantation is the only hope for patients with terminal. Indication and Prognosis of Liver Transplantation. Abstract
Indication and Prognosis of Liver Transplantation Jae Won Joh, M.D. Department of General Surgery Sungkyunkwan University School of Medicine Samsung Medical Center E mail: jwjoh@smc.samsung.co.kr Abstract
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationWithdrawal of Immunosuppression in Pediatric Liver Transplant Recipients in Korea
Original Article DOI 10.3349/ymj.2009.50.6.784 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 50(6): 784-788, 2009 Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients in Korea Jee
More informationA wig et all have highlighted a histological lesion
Centrilobular Necrosis After Orthotopic Liver Transplantation: A Longitudinal Clinicopathologic Study in 71 Patients Bmno Turlin, * Gabriella I. Slapah, * Karen M. Hayllar, * Nigel Heaton, f Roger Williams,
More informationE nd stage liver disease due to hepatitis C virus infection
248 LIVER DISEASE Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, R F Harrison, P J Gow, D Mutimer... Gut 2002;51:248 252 See end of article for
More information/03/ /0 TRANSPLANTATION Vol. 75, , No. 7, April 15, 2003 Copyright 2003 by Lippincott Williams & Wilkins, Inc.
0041-1337/03/7507-1020/0 TRANSPLANTATION Vol. 75, 1020 1025, No. 7, April 15, 2003 Copyright 2003 by Lippincott Williams & Wilkins, Inc. Printed in U.S.A. THE ABSENCE OF CHRONIC REJECTION IN PEDIATRIC
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationLiver Transplantation
1 Liver Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr History Development of Liver transplantation
More informationFibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes. Carla Venturi Monteagudo MD, PhD
Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes Carla Venturi Monteagudo MD, PhD THE NORMAL LIVER ARCHITECTURE Parenchymal Cells -Hepatocytes -Cholangiocytes
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationUpdate on Autoimmune Liver Disease. Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC
Update on Autoimmune Liver Disease Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth
More informationHow to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015
1 A Brief Introduction to the Liver Sessions 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology Sarajevo, 6 th -7 th November 2015 Stefan Hübscher, Institute of Immunology & Immunotherapy,
More informationHepatitis C virus (HCV)-cirrhosis is the most frequent
Contribution of Donor Age to the Recent Decrease in Patient Survival Among HCV-Infected Liver Transplant Recipients Marina Berenguer, 1 Martín Prieto, 1 Fernando San Juan, 2 José M. Rayón, 3 Fernando Martinez,
More informationRecurrence of autoimmune hepatitis (AIH) after
REVIEW ARTICLE Recurrent Autoimmune Hepatitis After Liver Transplantation: Diagnostic Criteria, Risk Factors, and Outcome Stefan G. Hübscher Approximately 20% to 30% of patients undergoing liver transplantation
More informationBritish Liver Transplant Group Pathology meeting September Leeds cases
British Liver Transplant Group Pathology meeting September 2014 Leeds cases Leeds Case 1 Male 61 years Liver transplant for HCV cirrhosis with HCC in January 2014. Now raised ALT and bilirubin,? acute
More informationCASE 01 LA Path Slide Seminar 13 March, 08. Deepti Dhall, MD Department of Pathology and Laboratory Medicine Cedars-Sinai Medical Center
CASE 01 LA Path Slide Seminar 13 March, 08 Deepti Dhall, MD Department of Pathology and Laboratory Medicine Cedars-Sinai Medical Center Clinical History 60 year old male presented with obstructive jaundice
More informationDhanpat Jain Yale University School of Medicine, New Haven, CT
Dhanpat Jain Yale University School of Medicine, New Haven, CT Case history 15 years old female presented with fatigue. Found to have features suggestive of cirrhosis with esophageal varices, splenomegaly
More informationIl trapianto di cellule staminali emopoietiche nel paziente portatore di virus epatitici
Il trapianto di cellule staminali emopoietiche nel paziente portatore di virus epatitici Anna Locasciulli Ematologia e Trapianto di Cellule Staminali Emopoietiche Ospedale S.Camillo, Roma Il trapianto
More informationAutoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015
Autoimmune Hepatitis What Drug and for How Long? Rajaa Chatila, MD Associate Professor of Medicine Director, Internal Medicine Residency Program Lebanese American University Hepatology Day May 30 th, 2015
More informationRole of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging
Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging for further reference: Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach Neil Theise, MD. Depts of Pathology
More informationBiochemical and Histopathological Correlation in Liver Transplant: The First 180 Days
Biochemical and Histopathological Correlation in Liver Transplant: The First 180 Days KEITH s. HENLEY,' MICHAEL R. LUCEY,~ HENRY D. APPELMAN,2 PRABHAKAR BALIGA,3 KIMBERLY A. BROWN,^ GORDON D. BURTCH,3
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationNon-infectious hepatic complications in patients with GVHD
Non-infectious hepatic complications in patients with GVHD Tapani Ruutu Helsinki University Central Hospital Liver dysfunction in allogeneic stem cell transplantation injury secondary to the cytoreductive
More informationDrug Induced Liver Disease Role of the Pathologist. Disclosure. DILI can never be excluded. Romil Saxena, MD. Dr. Saxena has nothing to Disclose
Drug Induced Liver Disease Role of the Pathologist Romil Saxena, MD Disclosure Dr. Saxena has nothing to Disclose DILI can never be excluded #1 DILI has no specific pattern of injury it can mimic any and
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationSupplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1
Supplemental Tables Supplemental Table 1 Various etiologies of liver cirrhosis and their association with liver stiffness and AST/ALT ratio Disease category Cause Example LS AST/ALT Inflammatory liver
More informationOverall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
More informationBiliary tract diseases of the liver
Biliary tract diseases of the liver Digestive Diseases Course Bucharest 2016 Rob Goldin r.goldin@imperial.ac.uk How important are biliary tract diseases? Hepatology 2011 53(5):1608-17 Approximately 16%
More informationAutoimmune Hepatitis: Histopathology
REVIEW Autoimmune Hepatitis: Histopathology Stephen A. Geller M.D.*, Autoimmune hepatitis (AIH), a chronic hepatic necroinflammatory disorder, occurs mostly in women. AIH is characterized by prominent
More informationDILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting
DILI PATHOLOGY PHILIP KAYE November 2017 BSG Pathology Winter Meeting General Mechanisms Role of Liver Biopsy Outline Kleiner Categories Pathology! Differentials Severity Finally Drugs/Toxins may cause
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust
ACP-BSG meeting 10.12.09 The liver in systemic inflammatory disorders Dr Adrian C Bateman Southampton University Hospitals NHS Trust Wide range of diseases General inflammatory disorders Connective tissue
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationHepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses
Hepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses Mario G. Pessoa,*00 Norah A. Terrault,*00 Linda D. Ferrell, Jill Detmer, Janice Kolberg, Mark L. Collins, Maurene Viele,
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationMinimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
LIVER TRANSPLANTATION 16:130-137, 2010 ORIGINAL ARTICLE Minimal But Significant Improvement in Survival for Non Hepatitis C Related Adult Liver Transplant Patients Beyond the One-Year Posttransplant Mark
More informationInduction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation
LIVER TRANSPLANTATION 12:1210-1214, 2006 ORIGINAL ARTICLE Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation Ashesh Shah, 1 Avinash Agarwal, 1 Richard Mangus,
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:98 103 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Serologic Markers Do Not Predict Histologic Severity or Response to Treatment in Patients With
More informationTreatment of HCV Recurrence: Do the Pretransplantation Rules Apply?
LIVER TRANSPLANTATION 12:1044-1048, 2006 EDITORIAL Treatment of HCV Recurrence: Do the Pretransplantation Rules Apply? James R. Burton, Jr., and Hugo R. Rosen Department of Medicine, Division of Gastroenterology
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationNoncirrhotic Portal Hypertension and Pathology of the Sinusoids. Ian R. Wanless Department of Pathology Dalhousie University Halifax, Canada
Noncirrhotic Portal Hypertension and Pathology of the Sinusoids Ian R. Wanless Department of Pathology Dalhousie University Halifax, Canada Non cirrhotic portal hypertension Extrahepatic portal vein obstruction
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationCurrently, the leading indication for liver transplantation
ORIGINAL ARTICLES Severe Recurrent Hepatitis C After Liver Retransplantation for Hepatitis C Virus Related Graft Cirrhosis Marina Berenguer, * Martín Prieto, * Antonio Palau, * José M. Rayón, Domingo Carrasco,
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationSpontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report
Hara et al. Surgical Case Reports (2016) 2:118 DOI 10.1186/s40792-016-0246-2 CASE REPORT Open Access Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis
More informationAutoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018
Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationI topic liver transplantation (OLT) to avoid organ
ORIGINAL ARTICLES Long-Term Immunosuppression Without Corticosteroids After Orthotopic Liver Transplantation: A Positive Therapeutic Aim Gerald M. Fraser, * Kons tantinos Grammous tianos, Jayendravandan
More informationHepatitis C virus (HCV)-induced cirrhosis is the leading
ORIGINAL ARTICLE Recurrent Hepatitis C in Liver Allografts Prospective Assessment of Diagnostic Accuracy, Identification of Pitfalls, and Observations About Pathogenesis A. J. Demetris, MD,* B. Eghtesad,
More informationAASLD: Boston Rob Goldin
AASLD: Boston 2014 Rob Goldin r.goldin@imperial.ac.uk Autoimmune hepatitis 31 Does genuine acute autoimmune hepatitis have a better prognosis? 32 Patients with Autoimmune Hepatitis and Advanced Disease
More informationPediatric Primary Sclerosing Cholangitis and Potential Therapies
Pediatric Primary Sclerosing Cholangitis and Potential Therapies Philip Rosenthal, M.D. Professor of Pediatrics & Surgery University of California, San Francisco DISCLOSURE I have the following financial
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationThey are a cure, yes. The good news is that a lot of what I was going to talk about has been covered very nicely this morning. So, I think what I am
They are a cure, yes. The good news is that a lot of what I was going to talk about has been covered very nicely this morning. So, I think what I am going to try to do is give you some examples of some
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationLeading article. Hepatitis C and liver transplantation
Gut 1999;45:159 163 159 Leading article Hepatitis C and liver transplantation Introduction Cirrhosis secondary to hepatitis C virus (HCV) infection, alone or in combination with alcohol, is the principal
More informationMost Relevant Pathology Issues in the Late Post Liver Transplant Period
Continued education in hepatopathology Most Relevant Pathology Issues in the Late Post Liver Transplant Period Rocío del Pilar López Panqueva, MD 1 1 Pathologist at the Hospital Universitario Fundación
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationBiopsy Features of Kidney Allograft Rejection Banff B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Biopsy Features of Kidney Allograft Rejection Banff 2017 B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary Treatment of allograft dysfunction should rely on the biopsy findings
More informationSerum Hepatitis C Virus RNA Levels and Histologic Findings in Liver Allografts With Early Recurrent Hepatitis C
Serum Hepatitis C Virus RNA Levels and Histologic Findings in Liver Allografts With Early Recurrent Hepatitis C Young Nyun Park, MD; Peter Boros, MD, PhD; David Y. Zhang, MD, PhD; Patricia Sheiner, MD;
More informationViral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel. Basel,
Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel Basel, 19. 04. 2016 Definition Hepatitis means inflammation of the liver characterized by a variable combination
More information